Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

6,6′-Trehalose dioleate (6,6′-TDO) is a glycolipid that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of mRNA in vitro and in vivo.1 LNPs containing 6,6′-TDO and encapsulating mRNA encoding influenza A hemagglutinin A (HA) increase Ifn-γ, Il-2, and Tnf-α secretion by isolated mouse splenocytes. LNPs containing 6,6′-TDO accumulate in the liver and spleen after intramuscular administration in mice. Unlike LNP formulations that do not contain 6,6′-TDO, LNPs containing 6,6′-TDO do not decrease serum levels of blood urea nitrogen (BUN) or increase serum levels of lactate dehydrogenase (LDH), troponin I, alanine transaminase (ALT), and aspartate aminotransferase (AST) in mice. LNPs containing 6,6′-TDO and encapsulating mRNA encoding influenza A HA increase serum IgG1 and IgG2a titers in mice.
WARNING This product is not for human or veterinary use.
1. A lipid nanoparticle platform incorporating trehalose glycolipid for exceptional mRNA vaccine safety. Bioact. Mater. 38, 486-498 (2024).